Efficacy and safety of once-daily regimens in the treatment of HIV infection.
about
Evaluating the role of atazanavir/cobicistat and darunavir/cobicistat fixed-dose combinations for the treatment of HIV-1 infectionOral pre-exposure prophylaxis (PrEP) for prevention of HIV in serodiscordant heterosexual couples in the United States: opportunities and challengesReassuring Birth Outcomes With Tenofovir/Emtricitabine/Efavirenz Used for Prevention of Mother-to-Child Transmission of HIV in BotswanaShort communication: fasting increases serum concentrations of bilirubin in patients receiving atazanavir: results from a pilot study.A novel polymorphism in ABCB1 gene, CYP2B6*6 and sex predict single-dose efavirenz population pharmacokinetics in Ugandans.HIV protease inhibitors: recent clinical trials and recommendations on use.Plasma Efavirenz Exposure, Sex, and Age Predict Virological Response in HIV-Infected African Children.Cobicistat: a review of its use as a pharmacokinetic enhancer of atazanavir and darunavir in patients with HIV-1 infection.Emtricitabine/rilpivirine/tenofovir disoproxil fumarate single-tablet regimen: a review of its use in HIV infection.Abacavir-induced reaction with fever and severe skin rash in a patient tested human leukocyte antigen-B*5701 negative.Pharmacokinetic study of once-daily versus twice-daily abacavir and lamivudine in HIV type-1-infected children aged 3-<36 months.Incidence of hyperbilirubinemia and jaundice due to atazanavir in a cohort of Hispanic patients.Correlates of HAART adherence among immigrant Latinos in the Southeastern United States.Efficacy and safety of ritonavir-boosted and unboosted atazanavir among antiretroviral-naïve patients.Theoretical studies of HIV-1 reverse transcriptase inhibition.
P2860
Q26750406-1B4B1F4A-9E5F-42E0-859A-C55A44FF6D36Q27023352-4AEF8028-E08F-4652-B902-AA8F124CADB2Q36619600-8A8FD042-01BC-4BCF-9463-02DE668879FDQ36634838-91AF3269-5E74-4BA0-BA5C-E3E166592BB8Q37471061-B25A52B7-849C-4CDE-89BC-E1DE98C3D3A9Q37519715-3806A1B3-A6EF-4178-9800-E68F0D67A1D3Q37519804-43557327-A6F5-4C88-BCDA-6E8C106471CDQ38171753-5FA0DADF-7706-4883-8DF6-9B71D21B8C61Q38263470-7953B7AB-9EAC-4F90-93D3-B8E196BAEF34Q40394091-B90BC84D-85C0-451F-B20A-BCF92E00067AQ41881433-94D594A1-DE02-4B71-BBE8-69081EC3635AQ43240844-87F71AE5-2101-49B8-9E68-2887BBA912F0Q44312643-FD39B7B3-9F16-4D94-8261-AF821B3B5BB5Q46127996-7BC961B2-EEE4-4FE2-BC5B-D392809B6DE6Q54495575-3257EAB5-356D-41C3-B7BE-64CEA4C07D5C
P2860
Efficacy and safety of once-daily regimens in the treatment of HIV infection.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Efficacy and safety of once-daily regimens in the treatment of HIV infection.
@en
Efficacy and safety of once-daily regimens in the treatment of HIV infection.
@nl
type
label
Efficacy and safety of once-daily regimens in the treatment of HIV infection.
@en
Efficacy and safety of once-daily regimens in the treatment of HIV infection.
@nl
prefLabel
Efficacy and safety of once-daily regimens in the treatment of HIV infection.
@en
Efficacy and safety of once-daily regimens in the treatment of HIV infection.
@nl
P1433
P1476
Efficacy and safety of once-daily regimens in the treatment of HIV infection.
@en
P2093
Jean-Michel Molina
P304
P356
10.2165/00003495-200868050-00001
P577
2008-01-01T00:00:00Z
P6179
1043814320